Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Jack H, Ladenson"'
Autor:
Claude Steriade, Neill R. Graff-Radford, A. Sebastian Lopez-Chiriboga, Marvin J Fritzler, Warren Mason, Harald Prüss, Gregory S. Day, Robert C. Bucelli, Anne Fagan, Rachel L Henson, Melanie Y Yarbrough, Jack H. Ladenson, John C. Morris, Julien Hébert, David F. Tang-Wai, Elizabeth M Herries, Peter Md Körtvelyessy
Publikováno v:
Neurology
ObjectiveTo determine whether neuronal and neuroaxonal injury, neuroinflammation, and synaptic dysfunction associate with clinical course and outcomes in antibody-mediated encephalitis (AME), we measured biomarkers of these processes in CSF from pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f503765c99dcb2b0f867dc6d66aff25
https://pubmed.ncbi.nlm.nih.gov/34233943
https://pubmed.ncbi.nlm.nih.gov/34233943
Autor:
Kaj Blennow, Anne M. Fagan, Ulf Andreasson, Sebastiaan Engelborghs, Charlotte E. Teunissen, Elizabeth M. Herries, Henrik Zetterberg, Wiesje M. van der Flier, Ann De Vos, Philip Scheltens, Eugeen Vanmechelen, Maria Bjerke, Dan L. Crimmins, Eline A.J. Willemse, Jack H. Ladenson
Publikováno v:
Clinical chemistry : international journal of laboratory medicine and molecular diagnostics
Willemse, E A J, De Vos, A, Herries, E M, Andreasson, U, Engelborghs, S, Van Der Flier, W M, Scheltens, P, Crimmins, D, Ladenson, J H, Vanmechelen, E, Zetterberg, H, Fagan, A M, Blennow, K, Bjerke, M & Teunissen, C E 2018, ' Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease : An assay comparison study ', Clinical Chemistry, vol. 64, no. 6, pp. 927-937 . https://doi.org/10.1373/clinchem.2017.283028
Clinical Chemistry, 64(6), 927-937. Oxford University Press
Willemse, E A J, De Vos, A, Herries, E M, Andreasson, U, Engelborghs, S, Van Der Flier, W M, Scheltens, P, Crimmins, D, Ladenson, J H, Vanmechelen, E, Zetterberg, H, Fagan, A M, Blennow, K, Bjerke, M & Teunissen, C E 2018, ' Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease : An assay comparison study ', Clinical Chemistry, vol. 64, no. 6, pp. 927-937 . https://doi.org/10.1373/clinchem.2017.283028
Clinical Chemistry, 64(6), 927-937. Oxford University Press
BACKGROUND Neurogranin in cerebrospinal fluid (CSF) correlates with cognitive decline and is a potential novel biomarker for Alzheimer disease (AD) dementia. We investigated the analytical and diagnostic performance of 3 commonly used neurogranin ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75a41e4c8711c399a33bbf50f757484e
http://www.scopus.com/inward/record.url?scp=85047958635&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85047958635&partnerID=8YFLogxK
Autor:
Jack H. Ladenson
Publikováno v:
The Journal of Applied Laboratory Medicine. 5:229-231
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df6b9dfb86ede224e4f5bca2c75f6ce1
https://doi.org/10.1373/jalm.2019.029603
https://doi.org/10.1373/jalm.2019.029603
Obstructive sleep apnea decreases central nervous system-derived proteins in the cerebrospinal fluid
Autor:
Gina Jerome, Mary Beth Finn, David M. Holtzman, Jack H. Ladenson, Elizabeth M. Herries, Yo-El Ju, Daniel L. Crimmins, Anne M. Fagan, Courtney L. Sutphen
Publikováno v:
Annals of Neurology. 80:154-159
We hypothesized that one mechanism underlying the association between obstructive sleep apnea (OSA) and Alzheimer's disease is OSA leading to decreased slow wave activity (SWA), increased synaptic activity, decreased glymphatic clearance, and increas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6cee7bfee94297d162c7eff7bbbeab8
https://doi.org/10.1002/ana.24672
https://doi.org/10.1002/ana.24672
Autor:
Randall J. Bateman, Neill R. Graff-Radford, Anne M. Fagan, Mathias Jucker, Chengjie Xiong, Carlos Cruchaga, Tammie L.S. Benzinger, John C. Morris, Suzanne E. Schindler, Jack H. Ladenson, Jasmeer P. Chhatwal, David M. Holtzman, Julia D. Gray, Kaitlin W. Todd, Rachel L. Henson, Leslie M. Shaw, John Q. Trojanowski, Danielle Graham, John M. Ringman, Yan Li, Johannes Levin, Jason Hassenstab, Guoqiao Wang, Elizabeth M. Herries, James M. Noble
Publikováno v:
Alzheimers Dement
Alzheimer's and dementia 15(5), 655-665 (2019). doi:10.1016/j.jalz.2018.12.019
Alzheimer's and dementia 15(5), 655-665 (2019). doi:10.1016/j.jalz.2018.12.019
Introduction Four less well-studied but promising "emerging" cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin, synaptosomal-associated protein-25 (SNAP-25), visinin-like protein 1 (VILIP-1), and chit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9152f9961b868cf4225efd33132210eb
https://pubmed.ncbi.nlm.nih.gov/30846386
https://pubmed.ncbi.nlm.nih.gov/30846386
Autor:
Brian A. Gordon, Anne M. Fagan, Tammie L.S. Benzinger, Courtney L. Sutphen, Chengjie Xiong, Jack H. Ladenson, Suzanne E. Schindler, Elizabeth M. Herries, Carlos Cruchaga
Publikováno v:
Alzheimer's & Dementia. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::432661d90921f3f2dc11df66103e0c8f
https://doi.org/10.1016/j.jalz.2018.07.097
https://doi.org/10.1016/j.jalz.2018.07.097
Autor:
Dan L. Crimmins, Niklas Mattsson, Pashtun Shahim, Kaj Blennow, Henrik Zetterberg, Yelverton Tegner, Jack H. Ladenson, Elizabeth M. Macy
Publikováno v:
Brain Injury. 29:872-876
Visinin-like protein-1 (VILIP-1) has shown potential utility as a biomarker for neuronal injury in cerebrospinal fluid. This study investigated serum VILIP-1 as a diagnostic and prognostic marker in sports-related concussion.This multi-centre prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68cd430fe3f88d060bdd96681bf1afb2
https://doi.org/10.3109/02699052.2015.1018324
https://doi.org/10.3109/02699052.2015.1018324
Autor:
David M. Holtzman, Chengjie Xiong, Lena McCue, Elizabeth M. Herries, Courtney L. Sutphen, Jack H. Ladenson, Anne M. Fagan
Publikováno v:
Alzheimer's & dementia : the journal of the Alzheimer's Association
Introduction Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within-person biomarker(s) change over time is critical for trial enrollment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11df890a917cd9ab9480aeccc00d6932
https://pubmed.ncbi.nlm.nih.gov/29580670
https://pubmed.ncbi.nlm.nih.gov/29580670
Publikováno v:
Alzheimer's & Dementia. 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e546f23a9adcef41be3443ee73b56c22
https://doi.org/10.1016/j.jalz.2017.06.1418
https://doi.org/10.1016/j.jalz.2017.06.1418
Autor:
Eline A.J. Willemse, Ulf Andreasson, Maria Bjerke, Philip Scheltens, Charlotte E. Teunissen, Anne M. Fagan, Eugeen Vanmechelen, Henrik Zetterberg, Kaj Blennow, Elizabeth M. Herries, Jack H. Ladenson, Wiesje M. van der Flier, Ann De Vos, Sebastiaan Engelborghs
Publikováno v:
Alzheimer's & Dementia. 13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64dd3f224fc3e6089c752d304ef87a05
https://doi.org/10.1016/j.jalz.2017.07.061
https://doi.org/10.1016/j.jalz.2017.07.061